Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial.
Saby George, Ulka Vaishampayan, Alan Hutson, Adrienne Groman, Roberto Pili, Kelly Green, Laurie Herbst, Rushka Kallicharan-Smith, Ann-Marie DiRaddo, Elongia Farrell, Dharmesh Gopalakrishnan, Elisabeth Heath, Elizabeth Wulff, Deepak Kilari, Leonard Appleman, Rahul Parikh
Lancet Oncol S1470-2045(26)00394-3
摘要
摘要
BACKGROUND: VEGFR tyrosine kinase inhibitors (TKIs) are considered the backbone for the treatment of metastatic clear-cell renal cell carcinoma. We hypothesise that the administration of bevacizumab during scheduled breaks in pazopanib (TKI) treatment can improve tolerability and prolong progression-free survival compared with historical controls. METHODS: In this single-arm, phase 1/2 trial in five US academic cancer centres, patients (aged ≥18 years) with histologically confirmed metastatic clear-cell renal cell carcinoma, Eastern Cooperative Oncology Group performance status of 1 or less, and adequate organ functions were included. The phase 1 portion included patients with up to one previous therapy with high-dose IL-2 or an anti-PD-1 compound alone or in combination with a CTLA-4 inhibitor. The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma. The primary endpoint of phase 1 was to find the recommended phase 2 dose (RP2D). We tested a novel regimen using four dose levels: oral pazopanib (600 or 800 mg daily on days 1-28, followed by a 7 day break) alternating with intravenous bevacizumab (5, 7·5, or 10 mg/kg, one on day 36 and one on day 50) on a 10-week cycle in patients with metastatic clear-cell renal cell carcinoma naive to TKI treatment. The primary endpoint of phase 2 was median progression-free survival, assessed by a masked central statistician review. Dose selection (in patients who had completed 15 weeks) and activity (in patients who had completed one full 10-week cycle of the novel regimen) were analysed in the per-protocol population. Safety analyses included all patients who received any treatment. This trial was registered with ClinicalTrials.gov (NCT01684397) and is ongoing but closed to new participants. FINDINGS: Between Nov 21, 2012, and June 11, 2018, phase 1 enrolled 25 patients, with 18 patients evaluable for dose-limiting toxicity during the extended 15-week safety assessment period. The RP2D was established as pazopanib 800 mg daily (days 1-28) and bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle. Between Jan 23, 2019, and Oct 19, 2023, phase 2 enrolled 53 patients, of whom 51 (including six from phase 1) were evaluable for activity and 59 were evaluable for safety. 36 (71%) patients were male and 15 (29%) were female, and 48 (94%) patients were White. 33 (65%) patients in phase 2 had favourable risk per the International Metastatic Renal Cell Carcinoma Database Consortium categories. After a median follow-up of 63·7 months (IQR 16·2-73·5), median progression-free survival was 24·8 months (95% CI 17·2-34·3). The most common grade 3-4 treatment-related adverse events were hypertension (20 [34%] of 59) and elevated aspartate aminotransferase (seven [12%]) and alanine aminotransferase (ten [17%]). Five (8%) patients discontinued the study for drug-related serious adverse events. No treatment-related deaths occurred. INTERPRETATION: The phase 1 portion identified the safe RP2D. The phase 2 portion showed that this novel regimen has promising antitumour activity in patients with metastatic clear-cell renal cell carcinoma in the predominantly favourable risk group who are naive to treatment. Phase 3 randomised controlled trial data are needed to confirm these findings. FUNDING: The Roswell Park Comprehensive Cancer Center (RPCCC), US National Cancer Institute (NCI), Novartis.
KM 提取结果
0 个 Figure · 0 个 KM 面板